ProCE Banner Activity

Hepatitis Delta in Focus: Episode 2 of Answering the Questions on Screening, Diagnosis, and Treatment

Podcast Episodes

In this podcast episode, listen to expert faculty perspectives on HDV management, including limitations to AASLD screening recommendations, use of double reflex testing, approaches to staging advanced liver disease, considerations for treatment, and clinical trial updates.

Released: April 27, 2023

Share

Faculty

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Stefan Zeuzem

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., and Janssen Therapeutics Division of Janssen Products.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Disclosure

Primary Author

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Bausch, Gilead; researcher: Gilead.

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD: consultant/advisor/speaker: AbbVie, BioMarin, Gilead, GlaxoSmithKline, Intercept, Janssen, MSD/Merck, Novo Nordisk, Sobi.